Search
Research
Early Peanut Immunotherapy in Children (EPIC) trial: Protocol for a pragmatic randomised controlled trial of peanut oral immunotherapy in children under 5 years of ageFood allergy is a major public health challenge in Australia. Despite widespread uptake of infant feeding and allergy prevention guidelines the incidence of peanut allergy in infants has not fallen, and prevalence of peanut allergy in school-aged children continues to rise. Therefore, effective and accessible treatments for peanut allergy are required.
Research
The gut microbiota and inflammatory noncommunicable diseases: Associations and potentials for gut microbiota therapiesThis article discusses the relationships between gut colonization & inflammatory noncommunicable diseases, in regards to their treatment and prevention.
Research
Mechanisms of allergic disease - environmental and genetic determinants for the development of allergyEnvironmental exposures including maternal inflammation, diet, nutrient balance, microbial colonization and toxin exposures can directly and indirectly...
Research
Effects of maternal dietary egg intake during early lactation on human milk ovalbumin concentration: A randomized controlled trialIncreased maternal egg ingestion is associated with increased breastmilk ovalbumin, and markers of immune tolerance in infants
Research
Consensus of stakeholders on precautionary allergen labelling: A report from the Centre for Food and Allergy ResearchPrecautionary allergen labelling is the main tool available to indicate safety levels for food-allergic consumers with regard to potential allergens
Research
Gene polymorphisms, breast-feeding, and development of food sensitization in early childhoodThe effect of breast-feeding on the development of allergic disease is uncertain
Research
Study protocol of a multicentre, randomised, controlled trial evaluating the effectiveness of probiotic and peanut oral immunotherapy in inducing desensitisation or tolerance in children with peanut allergy compared with oral immunotherapyPeanut allergy is the the most common cause of life-threatening food-induced anaphylaxis. There is currently no effective long-term treatment. There is a pressing need for definitive treatments that improve the quality of life and prevent fatalities.
Research
Allergen Specific IgE is a Stronger Predictor of Remission Following Peanut Oral Immunotherapy Than Age in Children Aged 1–10 YearsRemission is the desired outcome following OIT as it allows individuals to discontinue treatment and eat the allergen freely. Early initiation of OIT in infants and toddlers has been embraced as an approach to increase the likelihood of remission. However, there is no high-quality evidence supporting younger age as an independent factor driving remission; available studies are limited by small samples of younger subjects and lack of adjustment for confounding covariates, particularly peanut-specific IgE (sIgE) levels which is closely cor
Research
Impaired calcium influx underlies skewed T helper cell differentiation in children with IgE-mediated food allergiesReasons for Th2 skewing in IgE-mediated food allergies remains unclear. Clinical observations suggest impaired T cell activation may drive Th2 responses evidenced by increased atopic manifestations in liver transplant patients on tacrolimus (a calcineurin inhibitor). We aimed to assess differentiation potential, T cell activation and calcium influx of naïve CD4+ T cells in children with IgE-mediated food allergies.
Research
A newborn's perspective on immune responses to foodIn this review, we will highlight infants' immune responses to food, emphasizing the unique aspects of early-life immunity and the critical role of breast milk as a food dedicated to infants. Infants are susceptible to inflammatory responses rather than immune tolerance at the mucosal and skin barriers, necessitating strategies to promote oral tolerance that consider this susceptibility.